{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:37:53Z","timestamp":1784828273003,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.seizure.2021.08.019","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:44:24Z","timestamp":1630449864000},"page":"112-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Treatment outcomes in drug resistant juvenile myoclonic epilepsy: Valproate resistance may not be the end of the road"],"prefix":"10.1016","volume":"92","author":[{"given":"Neeraj","family":"Baheti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaturbhuj","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atma Ram","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari Kunhi","family":"Veedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyani","family":"Kanhere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam K.","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis","family":"Jukkarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagarlapudi M.K.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurupath","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"S1","key":"10.1016\/j.seizure.2021.08.019_bib0001","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.yebeh.2012.06.024","article-title":"Epidemiology of juvenile myoclonic epilepsy","volume":"28","author":"Camfield","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"S9","key":"10.1016\/j.seizure.2021.08.019_bib0002","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2005.00309.x","article-title":"Epidemiology of idiopathic generalized epilepsies","volume":"46","author":"Jallon","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.08.019_bib0003","series-title":"Epilepsy, A Comprehensive Textbook","first-page":"2389","article-title":"Juvenile myoclonic epilepsy","author":"Janz","year":"1998"},{"key":"10.1016\/j.seizure.2021.08.019_bib0004","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/brain\/awl048","article-title":"Juvenile myoclonic epilepsy subsyndromes: family studies and long-term follow-up","volume":"129","author":"Mart\u00ednez-Ju\u00e1rez","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.seizure.2021.08.019_bib0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/seiz.2000.0432","article-title":"Characteristics of valproic acid resistant juvenile myoclonic epilepsy","volume":"9","author":"Fernando-Dongas","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.08.019_bib0006","first-page":"240","article-title":"Clinical factors of drug resistance in juvenile myoclonic epilepsy","volume":"70","author":"Gelisse","year":"2001","journal-title":"JNNP"},{"key":"10.1016\/j.seizure.2021.08.019_bib0007","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/epi.13702","article-title":"Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies","volume":"58","author":"Gesche","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.08.019_bib0008","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/ene.13811","article-title":"Refractory juvenile myoclonic epilepsy: a meta-analysis of prevalence and risk factors","volume":"26","author":"Stevelink","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.seizure.2021.08.019_bib0009","doi-asserted-by":"crossref","first-page":"e2519","DOI":"10.1212\/WNL.0000000000010644","article-title":"Patterns and prognostic markers for treatment response in generalized epilepsies","volume":"95","author":"Gesche","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2021.08.019_bib0010","first-page":"1","article-title":"Diagnostic and therapeutic approach to drug-resistant juvenile myoclonic epilepsy","author":"Ascoli","year":"2021","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.seizure.2021.08.019_bib0011","first-page":"75","article-title":"The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies","volume":"75","author":"Nicolson","year":"2004","journal-title":"JNNP"},{"key":"10.1016\/j.seizure.2021.08.019_bib0012","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2021.08.019_bib0013","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/ana.21166","article-title":"Likelihood of seizure remission in an adult population with refractory epilepsy","volume":"62","author":"Callaghan","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2021.08.019_bib0014","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ana.21064","article-title":"Results of treatment changes in patients with apparently drug-resistant chronic epilepsy","volume":"62","author":"Luciano","year":"2007","journal-title":"Ann Neurol"},{"issue":"Suppl1","key":"10.1016\/j.seizure.2021.08.019_bib0015","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.yebeh.2012.11.051","article-title":"Consensus on diagnosis and management of JME: from founder\u2019s observations to current trends","volume":"28","author":"Kasteleijn-NolstTrenit\u00e9","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2021.08.019_bib0016","unstructured":"International league against epilepsy. EpilepsyDiagnosis.org:Juvenile myoclonic epilepsy. https:\/\/www.epilepsydiagnosis.org\/syndrome\/jme-overview.html. Accessed March 10, 2021."},{"key":"10.1016\/j.seizure.2021.08.019_bib0017","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1212\/WNL.55.8.1106","article-title":"Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy?","volume":"55","author":"Genton","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2021.08.019_bib0018","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.08.019_bib0019","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11096-017-0447-1","article-title":"Correlation between prescribed daily dose, seizure freedom and defined daily dose in antiepileptic drug treatment","volume":"39","author":"Horv\u00e1th","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.seizure.2021.08.019_bib0020","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2021.08.019_bib0021","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2021.08.019_bib0022","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.0b013e31823ed0dd","article-title":"Comparative efficacy of combination drug therapy in refractory epilepsy","volume":"78","author":"Poolos","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2021.08.019_bib0023","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1528-1157.1999.tb00832.x","article-title":"The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a phramcodynamic interaction","volume":"40","author":"Pisani","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.08.019_bib0024","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.55.4.588","article-title":"Adding valproate to lamotrigine: a study of their pharmacokinetic interaction","volume":"54","author":"Kanner","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2021.08.019_bib0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2217\/pgs-2019-0179","article-title":"Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study","volume":"21","author":"Wolking","year":"2020","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.seizure.2021.08.019_bib0026","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs:a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2021.08.019_bib0027","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study):a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2021.08.019_bib0028","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(18)31672-6","article-title":"New regulations to cut valproate-exposed pregnancies","volume":"392","author":"Sen","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2021.08.019_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.seizure.2017.12.008","article-title":"Unblinded, randomized multicenter trial comparing lamotrigine and valproate combination with controlled-release carbamazepine monotherapy as initial drug regimen in untreated epilepsy","volume":"55","author":"Lee","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.08.019_bib0030","doi-asserted-by":"crossref","first-page":"e1822","DOI":"10.1212\/WNL.0000000000006472","article-title":"Generalized polyspike train: an EEG biomarker of drug-resistant idiopathic generalized epilepsy","volume":"91","author":"Sun","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2021.08.019_bib0031","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/epi4.12349","article-title":"EpiPGX consortium. comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy","volume":"4","author":"Silvennoinen","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.seizure.2021.08.019_bib0032","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/CPJ.0000000000000722","article-title":"Clinical utility of therapeutic drug monitoring of antiepileptic drugs: systematic review","volume":"10","author":"Al-Roubaie","year":"2020","journal-title":"Neurol Clin Pract"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121002971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121002971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:59:30Z","timestamp":1761011970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131121002971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":32,"alternative-id":["S1059131121002971"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2021.08.019","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment outcomes in drug resistant juvenile myoclonic epilepsy: Valproate resistance may not be the end of the road","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2021.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}